Trial Profile
A NON-RANDOMIZED, MULTIPLE-DOSE, OPEN-LABEL, SINGLE SEQUENCE STUDY TO EVALUATE THE EFFECT OF CONCOMITANT ADMINISTRATION OF EDP-235 ON THE PHARMACOKINETICS AND SAFETY OF MIDAZOLAM, CAFFEINE, AND ROSUVASTATIN IN HEALTHY PARTICIPANTS
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 May 2023
Price :
$35
*
At a glance
- Drugs Caffeine (Primary) ; EDP-235 (Primary) ; Midazolam (Primary) ; Rosuvastatin (Primary)
- Indications COVID 2019 infections
- Focus Pharmacokinetics
- Sponsors Enanta Pharmaceuticals
- 25 Apr 2023 Status changed from recruiting to completed.
- 28 Oct 2022 New trial record